---
title: Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
nct_id: NCT02396966
overall_status: COMPLETED
sponsor: Ipsen
study_type: OBSERVATIONAL
primary_condition: Acromegaly
countries: Poland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02396966.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02396966"
ct_last_update_post_date: 2018-12-21
last_seen_at: "2026-05-12T07:08:25.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.

**Official Title:** A Prospective, Non-interventional, Observational, Multi-centre Study to Document QoL of Subjects With Acromegaly Under Lanreotide Autogel® Treatment.

**NCT ID:** [NCT02396966](https://clinicaltrials.gov/study/NCT02396966)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 152
- **Lead Sponsor:** Ipsen
- **Conditions:** Acromegaly
- **Start Date:** 2014-12
- **Completion Date:** 2018-05
- **CT.gov Last Update:** 2018-12-21

## Brief Summary

The purpose of the protocol is to evaluate and describe QoL, in the population of Polish acromegalic patients treated with Lanreotide Autogel® 120 mg during the 24 months (long term observation).

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Adult patients with acromegaly treated for at least three months and no longer than three years with Lanreotide Autogel® 120 mg just before inclusion.
* Patients capable of giving their informed consent to participate in the study and who agree to participate by signing the informed consent form.

Exclusion Criteria:

* Active participation in any interventional or any other non-interventional acromegaly clinical study. (Previous participation in any interventional or any observational / post marketing study (PMS) of other somatostatin analogue should not be an exclusion criteria).
* Any medical or psychological condition, according to investigator judgement, that might compromise the ability to give informed consent.
```

## Primary Outcomes

- **Acromegaly quality of life (AcroQol) questionnaire** _(time frame: Change from baseline (visit 1), visit 3 and 6 (visits occur approximately every 4-5 months, during 2 years of observation))_ — The AcroQol questionnaire and total AcroQol score will be analysed descriptively overall and according to hormonal control, presence of prior radiotherapy, presence of prior surgery.

## Secondary Outcomes

- **Hormonal control of serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1) concentration** _(time frame: Visit 1 to 6 (visits occur approximately every 4-5 months, during 2 years of observation))_
- **Clinical symptoms of acromegaly** _(time frame: Visit 1 to 6 (visits occur approximately every 4-5 months, during 2 years of observation))_
- **Patient overall assessment of satisfaction from treatment** _(time frame: Visit 1 to 6 (visits occur approximately every 4-5 months, during 2 years of observation))_
- **Lanreotide injection interval (28, 42 or 56 days)** _(time frame: Visit 1 to 6 (visits occur approximately every 4-5 months, during 2 years of observation))_

## Locations (18)

- Bialystok, Poland
- Bydgoszcz, Poland
- Bytom, Poland
- Gdansk, Poland
- Gliwice, Poland
- Katowice, Poland
- Kielce, Poland
- Krakow, Poland
- Lodz, Poland
- Lublin, Poland
- Olsztyn, Poland
- Opole, Poland
- Poznan, Poland
- Rybnik, Poland
- Rzeszów, Poland
- Szczecin, Poland
- Warsaw, Poland
- Wroclaw, Poland

## Recent Field Changes (last 30 days)

- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.|bialystok||poland` — added _(2026-05-12)_
- `locations.|bydgoszcz||poland` — added _(2026-05-12)_
- `locations.|bytom||poland` — added _(2026-05-12)_
- `locations.|gdansk||poland` — added _(2026-05-12)_
- `locations.|gliwice||poland` — added _(2026-05-12)_
- `locations.|katowice||poland` — added _(2026-05-12)_
- `locations.|kielce||poland` — added _(2026-05-12)_
- `locations.|krakow||poland` — added _(2026-05-12)_
- `locations.|lodz||poland` — added _(2026-05-12)_
- `locations.|lublin||poland` — added _(2026-05-12)_
- `locations.|olsztyn||poland` — added _(2026-05-12)_
- `locations.|opole||poland` — added _(2026-05-12)_
- `locations.|poznan||poland` — added _(2026-05-12)_
- `locations.|rybnik||poland` — added _(2026-05-12)_
- `locations.|rzeszów||poland` — added _(2026-05-12)_
- `locations.|szczecin||poland` — added _(2026-05-12)_
- `locations.|warsaw||poland` — added _(2026-05-12)_
- `locations.|wroclaw||poland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02396966.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02396966*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*